All News

Found 116 articles

• Adamis Provides an Enrollment Update on the Phase 2/3 Study of Tempol in COVID-19 Positive High-Risk Subjects

  9/12/2022

  Adamis Pharmaceuticals Corporation (NASDAQ: ADMP) today announced that the Company’s ongoing U.S. Phase 2/3 clinical trial to evaluate the safety and efficacy of Tempol as a treatment for COVID-19 has reached the initial planned enrollment of 248 subjects.

• High-Dose Naloxone Product Giving People Hope to Help Combat Growing Opioid Overdose Trend

  8/31/2022

  On International Overdose Awareness Day, community encouraged to learn about additional treatment options to help save lives.

• Adamis Pharmaceuticals Announces Results of Annual Meeting of Stockholders

  8/12/2022

  Adamis Pharmaceuticals Corporation (NASDAQ: ADMP) today announced that its 2022 Annual Meeting of Stockholders (“Annual Meeting”) was convened, as scheduled.

• Adamis Pharmaceuticals Reports Second Quarter 2022 Financial Results and Provides Corporate Update

  8/10/2022

  Adamis Pharmaceuticals Corporation reported financial results for the second quarter of 2022 and provided an update on recent corporate developments.

• Adamis Pharmaceuticals Schedules Second Quarter 2022 Financial Results Conference Call and Corporate Update

  8/8/2022

  Adamis Pharmaceuticals Corporation today announced that it will host an investor conference call on Wednesday, August 10, 2022 at 1:30 p.m. Pacific Time to discuss its financial and operating results for the second quarter 2022 as well as provide a corporate update.

• Adamis Pharmaceuticals Provides Update on Clinical Study Assessing Tempol for the Treatment of COVID-19Interim DSMB review expected in late September

  7/29/2022

  Adamis Pharmaceuticals Corporation (NASDAQ: ADMP) today provided an update on the Company’s ongoing U.S. Phase 2/3 clinical trial to evaluate the safety and efficacy of Tempol as a treatment for COVID-19.

• Leading Independent Proxy Advisory Firm ISS Recommends Adamis Pharmaceuticals’ Stockholders Vote FOR Critical Proposals at Upcoming Annual Meeting

  7/29/2022

  Adamis Pharmaceuticals Corporation (Nasdaq: ADMP) today announced that Institutional Shareholder Services Inc. ("ISS"), a leading independent proxy advisory firm, has recommended the Company’s stockholders vote FOR Proposal #2 and Proposal #3 on the agenda at the upcoming Annual Meeting of Stockholders (the “Annual Meeting”) on August 12, 2022.

• Adamis Pharmaceuticals Issues Letter to Stockholders

  7/21/2022

  Adamis Pharmaceuticals Corporation issued the following letter to stockholders from Chief Executive Officer David J. Marguglio.

• Adamis Appoints Vickie Reed to Board of Directors

  5/26/2022

  Adamis Pharmaceuticals Corporation announced the appointment of Vickie Reed as a new director and member of the company’s board of directors.

• Adamis Pharmaceuticals Announces Leadership Transition to Support New Phase of Innovation and Growth

  5/18/2022

  Adamis Pharmaceuticals Corporation (NASDAQ: ADMP), a biopharmaceutical company developing and commercializing specialty products for allergy, opioid overdose, respiratory and inflammatory diseases, today announced a leadership transition plan to support its efforts to unlock long-term growth and value creation opportunities:

• Adamis Pharmaceuticals Reports First Quarter 2022 Financial Results and Provides Corporate Update

  5/16/2022

  Adamis Pharmaceuticals Corporation, a biopharmaceutical company developing and commercializing specialty products for allergy, opioid overdose, respiratory and inflammatory disease, announced financial results for the quarter ending March 31, 2022.

• Adamis Pharmaceuticals Schedules First Quarter 2022 Financial Results Conference Call and Business Update

  5/9/2022

  Adamis Pharmaceuticals Corporation (NASDAQ: ADMP), a biopharmaceutical company developing and commercializing specialty products for allergy, opioid overdose, respiratory and inflammatory disease, today announced that it will host an investor conference call on Monday, May 16, 2022 at 2 p.m. Pacific Time to discuss its financial and operating results for the first quarter 2022 as well as provide a business update.

• Adamis Pharmaceuticals Reports Full Year 2021 Financial Results and Provides Corporate Update

  3/31/2022

  Adamis Pharmaceuticals Corporation, a biopharmaceutical company developing and commercializing specialty products for allergy, opioid overdose, respiratory and inflammatory disease, announced financial results for the year ended December 31, 2021.

• US WorldMeds and Adamis Pharmaceuticals Announce U.S. Launch of ZIMHI™ Naloxone Product

  3/31/2022

  USWM, LLC, and Adamis Pharmaceuticals Corporation, announced the U.S. launch and availability of ZIMHI™ 5 mg/0.5 mL. ZIMHI is a high-dose naloxone injection product FDA-approved for use in the treatment of opioid overdose as emergency therapy in settings where opioids may be present.

• Adamis Pharmaceuticals Schedules Fourth Quarter and Full Year 2021 Financial Results Conference Call and Business Update

  3/24/2022

  Adamis Pharmaceuticals Corporation (NASDAQ: ADMP), today announced that it will host an investor conference call on Thursday, March 31, 2022 at 2 p.m. Pacific Time to discuss its financial and operating results for the fourth quarter and full year 2021 as well as provide a business update.

• Adamis Pharmaceuticals Announces Results of Tempol in Omicron Virus Challenge in Hamster Model

  3/22/2022

  Adamis Pharmaceuticals Corporation (Nasdaq: ADMP) today announced that in studies conducted at Galveston National Laboratory (GNL), University of Texas Medical Branch (UTMB) at Galveston, hamsters challenged with high levels of the Omicron variant of the SARS-CoV-2 virus, resulted in significant decrease of inflammation in the lungs of animals treated with Tempol compared to controls.

• Adamis Pharmaceuticals Provides Update on Clinical Study Assessing Tempol for the Treatment of COVID-19DSMB met to evaluate interim clinical and safety data and clears Phase 2/3 study to continue

  3/14/2022

  Adamis Pharmaceuticals Corporation (Nasdaq: ADMP) today announced that on March 11, 2022, the Data Safety Monitoring Board (DSMB) overseeing the Phase 2/3 clinical trial investigating the use of Tempol for the treatment of COVID-19, met to evaluate the clinical and safety data from the first planned interim analysis.

• Adamis Pharmaceuticals Announces Retirement of Richard C. Williams, Chairman of the Board

  3/4/2022

  Adamis Pharmaceuticals Corporation (NASDAQ: ADMP), today announced the retirement of Richard C. Williams, effective April 15, 2022.

• Adamis Pharmaceuticals’ Clinical Study Assessing Tempol for the Treatment of COVID-19 Surpasses Enrollment Expectations

  2/28/2022

  Adamis Pharmaceuticals Corporation  (Nasdaq: ADMP) today announced that due to the acceleration of patient enrollment in the double-blind placebo controlled Phase 2/3 trial for Tempol for the treatment of COVID-19.

• Adamis Announces Inducement Option Grants Under Nasdaq Listing Rule 5635(c)(4) - Feb 18, 2022

  2/18/2022

  Adamis Pharmaceuticals Corporation announced that the compensation committee of the board of directors and the company’s independent directors approved the grant of stock options on February 15, 2022, to purchase an aggregate of 130,000 shares of common stock to two non-officer employees who were not previously employees of the company.